Becton Dickinson (BDX-N) Stock Predictions - Stockchase
WATCH LIST
39
Becton Dickinson (BDX-N)

ON STOCKCHASE SINCE May 2003

disposable medical supplies

biotechnology/pharmaceutical

Becton Dickinson Becton Dickinson
BDX-N

19 39
biotechnology/pharmaceutical

Becton Dickinson (BDX-N) SAVE

238.09

1.71 (0.71%)

Oct, 20, 2018, 12:00 am

OPINIONS

About Becton Dickinson (BDX-N)

Becton, Dickinson and Company is an American medical technology company that manufactures and sells medical devices, instrument systems, and reagents. More at Wikipedia

What the experts are saying about BDX-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Becton Dickinson(BDX-N) 

August 24, 2018

(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it.

biotechnology/pharmaceutical

(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it.

biotechnology/pharmaceutical
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$255.400
Owned Owned
Yes

TOP PICK

A great up trending stock chart.  It is consolidating at the moment with lots of time to grow.  Yield 1.3%.  (Analysts’ price target is $251.11)

biotechnology/pharmaceutical

A great up trending stock chart.  It is consolidating at the moment with lots of time to grow.  Yield 1.3%.  (Analysts’ price target is $251.11)

biotechnology/pharmaceutical
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$231.610
Owned Owned
Yes

BUY
Becton Dickinson(BDX-N) 

April 23, 2018

U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics.

biotechnology/pharmaceutical

U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$233.020
Owned Owned
Yes

PAST TOP PICK
Becton Dickinson(BDX-N) 

March 28, 2018

(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years.

biotechnology/pharmaceutical

(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$212.430
Owned Owned
Yes

PARTIAL BUY
Becton Dickinson(BDX-N) 

February 21, 2018

He sees this as a good company, but not in his top 25.  Healthcare technology has been very profitable and medical consumables is a niche area.  There is good opportunity to grow through value add like prefilled syringes.    He sees them as a high quality, low cost provider.  

biotechnology/pharmaceutical

He sees this as a good company, but not in his top 25.  Healthcare technology has been very profitable and medical consumables is a niche area.  There is good opportunity to grow through value add like prefilled syringes.    He sees them as a high quality, low cost provider.  

biotechnology/pharmaceutical
David Fingold

VP and Por, Dynamic Funds...

Price Price
$218.700
Owned Owned
Yes

BUY
Becton Dickinson(BDX-N) 

February 13, 2018

They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space.

biotechnology/pharmaceutical

They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space.

biotechnology/pharmaceutical
David Baskin

President, Baskin Wealth Manage...

Price Price
$215.400
Owned Owned
Yes

BUY
Becton Dickinson(BDX-N) 

February 6, 2018

It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.  

biotechnology/pharmaceutical

It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.  

biotechnology/pharmaceutical
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$227.520
Owned Owned
Yes

COMMENT
Becton Dickinson(BDX-N) 

January 29, 2018

Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.

biotechnology/pharmaceutical

Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$244.930
Owned Owned
Yes

TOP PICK
Becton Dickinson(BDX-N) 

January 4, 2018

Their acquisition closed at the end of the year and they now have a commanding position.  They will have great pricing power.  They are well managed.  (Analysts’ target: $245.00).

biotechnology/pharmaceutical

Their acquisition closed at the end of the year and they now have a commanding position.  They will have great pricing power.  They are well managed.  (Analysts’ target: $245.00).

biotechnology/pharmaceutical
David Baskin

President, Baskin Wealth Manage...

Price Price
$220.990
Owned Owned
Yes

TOP PICK
Becton Dickinson(BDX-N) 

November 7, 2017

A healthcare name in devices. They have the Bard C R (BCR-N) acquisition that should close before the end of the year, which will give them a mid-single digit accretion and nice cost synergies. They are in the devices space, where capital spending worldwide is strong and growing. They are good about using dividends to return capital to shareholders. Dividend yield of 1.3%. (Analysts' price target is $234.50.)

biotechnology/pharmaceutical

A healthcare name in devices. They have the Bard C R (BCR-N) acquisition that should close before the end of the year, which will give them a mid-single digit accretion and nice cost synergies. They are in the devices space, where capital spending worldwide is strong and growing. They are good about using dividends to return capital to shareholders. Dividend yield of 1.3%. (Analysts' price target is $234.50.)

biotechnology/pharmaceutical
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$221.270
Owned Owned
Yes

COMMENT
Becton Dickinson(BDX-N) 

October 16, 2017

Recently started buying this. For lack of a better way to describe it, this is like a full complete service provider for medical supplies to hospitals and clinics. They sell consumables such as syringes and catheters, and are trying to get more into drug delivery and software. Acquiring Bard C R (BCR-N). A great company and a good business to be in.

biotechnology/pharmaceutical

Recently started buying this. For lack of a better way to describe it, this is like a full complete service provider for medical supplies to hospitals and clinics. They sell consumables such as syringes and catheters, and are trying to get more into drug delivery and software. Acquiring Bard C R (BCR-N). A great company and a good business to be in.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$200.820
Owned Owned
Yes

HOLD
Becton Dickinson(BDX-N) 

September 14, 2017

He reduced some of his med-tech in January.  Almost every type of object that is used in the medical world is in their catalogue.  He wants to see how their acquisitions work out.  It is on his radar, but you are probably okay to hold it right now.

biotechnology/pharmaceutical

He reduced some of his med-tech in January.  Almost every type of object that is used in the medical world is in their catalogue.  He wants to see how their acquisitions work out.  It is on his radar, but you are probably okay to hold it right now.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$197.600
Owned Owned
No

TOP PICK
Becton Dickinson(BDX-N) 

August 29, 2017

Acquiring Bard C R Inc., and is essentially going to be a one stop shop for hospitals, providing the product, providing analytics, providing administration. They get 58% of revenue from the US, so there is a big opportunity in emerging markets. He sees 5% revenue growth for many years to come. Sees them reducing debt in the next 2-3 years, and maybe making another material acquisition. Dividend yield of 1.4%. (Analysts’ price target is $216.50.)

biotechnology/pharmaceutical

Acquiring Bard C R Inc., and is essentially going to be a one stop shop for hospitals, providing the product, providing analytics, providing administration. They get 58% of revenue from the US, so there is a big opportunity in emerging markets. He sees 5% revenue growth for many years to come. Sees them reducing debt in the next 2-3 years, and maybe making another material acquisition. Dividend yield of 1.4%. (Analysts’ price target is $216.50.)

biotechnology/pharmaceutical
Barry Schwartz

CIO & Port, Baskin Wealth Manage...

Price Price
$198.900
Owned Owned
Yes

TOP PICK

This started a long time ago making syringes and needles, and that’s pretty much been their core. It’s all consumables in the hospitals, etc. Just made a recent acquisition of CR Bard (BCR-N) in the urology business. Both companies generate consistently growing free cash flows. There’s a 10% bump to the dividend every year. This merger is going to give them some debt that should be paid off within the next 2 years. He likes the company at this price.

biotechnology/pharmaceutical

This started a long time ago making syringes and needles, and that’s pretty much been their core. It’s all consumables in the hospitals, etc. Just made a recent acquisition of CR Bard (BCR-N) in the urology business. Both companies generate consistently growing free cash flows. There’s a 10% bump to the dividend every year. This merger is going to give them some debt that should be paid off within the next 2 years. He likes the company at this price.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$184.130
Owned Owned
Yes

PAST TOP PICK
Becton Dickinson(BDX-N) 

November 21, 2011

(A Top Pick Aug 12/11. Down 8.41%.) Still likes. 38 consecutive years of dividend increases.
biotechnology/pharmaceutical
(A Top Pick Aug 12/11. Down 8.41%.) Still likes. 38 consecutive years of dividend increases.
biotechnology/pharmaceutical
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$71.840
Owned Owned
Yes

Showing 1 to 15 of 39 entries

No Comments.


You must be logged in to comment.

Successfully Saved Company
Successfully Saved Company